# A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)

> **NCT07227597** · PHASE1,PHASE2 · RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 170 (estimated)

## Conditions studied

- Small Cell Lung Cancer Extensive Stage

## Interventions

- **DRUG:** Gocatamig
- **DRUG:** I-DXd
- **DRUG:** Atezolizumab
- **DRUG:** Carboplatin
- **DRUG:** Etoposide
- **DRUG:** Rescue Medications

## Key facts

- **NCT ID:** NCT07227597
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-29
- **Primary completion:** 2030-11-29
- **Final completion:** 2030-12-30
- **Target enrollment:** 170 (ESTIMATED)
- **Last updated:** 2026-05-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07227597

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07227597, "A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT07227597. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*